Elgemtumab  (Synonyms: 依更妥单抗; LJM716)

Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Elgemtumab(LJM716)(i.v., 20 mg/kg,once)在 BT474 乳腺癌异种移植物的 SCID 小鼠中，可以使 pHER3 最大减少 52%，pAKT 最大减少 84 %；而在 BxPC-3 胰腺异种移植物的 SCID 小鼠中，导致 pHER3 的最大抑制为 86%，pAKT 的最大抑制为 74%^[1]。
Elgemtumab(LJM716)(20 mg/kg, every other day, 35 days)在 BT474 乳腺癌异种移植物的 NSG 小鼠中，可以减缓肿瘤生长^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1512559-37-3

液体

Colorless to light yellow

依更妥单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded HER3 Protein, Human (HEK293, His, solution, HY-P72625A) on AHC2 biosensor, can bind Elgemtumab with an affinity constant of <1.000E-11 M as determined in BLI assay.

• [1]. Andrew P Garner, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.  [Content Brief]